ERAS Stock Summary and Trading Ideas (Erasca | NASDAQ:ERAS)

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Erasca trades on the NASDAQ stock market under the symbol ERAS.

As of November 13, 2026, ERAS stock price declined to $15.66 with 8,304,957 million shares trading.

ERAS has a beta of 0.96, meaning it tends to be less sensitive to market movements. ERAS has a correlation of 0.01 to the broad based SPY ETF.

ERAS has a market cap of $5.48 billion. This is considered a Mid Cap stock.

In the last 3 years, ERAS traded as high as $24.28 and as low as $1.01.

The top ETF exchange traded funds that ERAS belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

ERAS has outperformed the market in the last year with a price return of +516.5% while the SPY ETF gained +13.4%. However, in the short term, ERAS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.3% vs -2.8% return in SPY. But in the last 2 weeks, ERAS shares have fared better than the market returning +9.1% compared to SPY -0.2%.

ERAS support price is $14.87 and resistance is $16.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ERAS shares will trade within this expected range on the day.